Cargando…
Estimating the cost of diagnosing HIV at birth in Lesotho
BACKGROUND: Infants with HIV infection, particularly those infected in utero, who do not receive antiretroviral therapy (ART) have high mortality in the first year of life. Virologic diagnostic testing is recommended by the World Health Organization between ages 4 and 6 weeks after birth. However, a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093690/ https://www.ncbi.nlm.nih.gov/pubmed/30110377 http://dx.doi.org/10.1371/journal.pone.0202420 |
_version_ | 1783347713950089216 |
---|---|
author | Tchuenche, M. Gill, M. M. Bollinger, L. Mofenson, L. Phalatse, M. Nchephe, M. Mokone, M. Tukei, V. Tiam, A. Forsythe, S. |
author_facet | Tchuenche, M. Gill, M. M. Bollinger, L. Mofenson, L. Phalatse, M. Nchephe, M. Mokone, M. Tukei, V. Tiam, A. Forsythe, S. |
author_sort | Tchuenche, M. |
collection | PubMed |
description | BACKGROUND: Infants with HIV infection, particularly those infected in utero, who do not receive antiretroviral therapy (ART) have high mortality in the first year of life. Virologic diagnostic testing is recommended by the World Health Organization between ages 4 and 6 weeks after birth. However, adding very early infant diagnosis (VEID) testing at birth has been suggested to enable earlier diagnosis and rapid treatment of in utero infection. We assessed the costs of adding VEID to the standard 6-week testing in Lesotho where coverage of PMTCT services is nearly universal. METHODS: Retrospective cost data were collected at eight health-care facilities in three districts participating in an observational prospective study that included birth testing as well as at the National Reference Laboratory in Lesotho, to investigate the cost-per-infection identified. Extrapolating to the national level, it was possible to estimate the impact of VEID on the identification of HIV-infected infants. RESULTS: The unit cost-per-VEID test in Lesotho in 2015 was $40.50. Major cost drivers were supplies/commodities (46%) and clinical labor (22%). In 2015, 66.3% of cohort study infants born at study facilities underwent VEID; one out of 199 infants had a positive HIV DNA PCR test at birth (0.5% potential in utero infection), yielding a cost of $8,060 per HIV-positive infant identified. Sensitivity analysis showed costs based on Lesotho costing data ranged from $810 to $16,194 per-infected child with varying in utero infection rates from 5% and 0.25%, respectively. With 11,157 HIV-exposed births nationally from pregnant women on PMTCT, 66.3% VEID coverage, and 0.5% in utero infection, 37 infants infected with HIV could have been identified at birth in 2015 and 8 early infant deaths potentially averted with immediate ART compared with waiting for 6-week testing. CONCLUSION: If Lesotho costing data from this pilot study were applied to different epidemic circumstances, the cost-per-infected child identified by adding VEID birth testing to standard 6-week testing was lowest when in utero infection rates were high (when HIV prevalence is high and PMTCT coverage is low). |
format | Online Article Text |
id | pubmed-6093690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-60936902018-08-30 Estimating the cost of diagnosing HIV at birth in Lesotho Tchuenche, M. Gill, M. M. Bollinger, L. Mofenson, L. Phalatse, M. Nchephe, M. Mokone, M. Tukei, V. Tiam, A. Forsythe, S. PLoS One Research Article BACKGROUND: Infants with HIV infection, particularly those infected in utero, who do not receive antiretroviral therapy (ART) have high mortality in the first year of life. Virologic diagnostic testing is recommended by the World Health Organization between ages 4 and 6 weeks after birth. However, adding very early infant diagnosis (VEID) testing at birth has been suggested to enable earlier diagnosis and rapid treatment of in utero infection. We assessed the costs of adding VEID to the standard 6-week testing in Lesotho where coverage of PMTCT services is nearly universal. METHODS: Retrospective cost data were collected at eight health-care facilities in three districts participating in an observational prospective study that included birth testing as well as at the National Reference Laboratory in Lesotho, to investigate the cost-per-infection identified. Extrapolating to the national level, it was possible to estimate the impact of VEID on the identification of HIV-infected infants. RESULTS: The unit cost-per-VEID test in Lesotho in 2015 was $40.50. Major cost drivers were supplies/commodities (46%) and clinical labor (22%). In 2015, 66.3% of cohort study infants born at study facilities underwent VEID; one out of 199 infants had a positive HIV DNA PCR test at birth (0.5% potential in utero infection), yielding a cost of $8,060 per HIV-positive infant identified. Sensitivity analysis showed costs based on Lesotho costing data ranged from $810 to $16,194 per-infected child with varying in utero infection rates from 5% and 0.25%, respectively. With 11,157 HIV-exposed births nationally from pregnant women on PMTCT, 66.3% VEID coverage, and 0.5% in utero infection, 37 infants infected with HIV could have been identified at birth in 2015 and 8 early infant deaths potentially averted with immediate ART compared with waiting for 6-week testing. CONCLUSION: If Lesotho costing data from this pilot study were applied to different epidemic circumstances, the cost-per-infected child identified by adding VEID birth testing to standard 6-week testing was lowest when in utero infection rates were high (when HIV prevalence is high and PMTCT coverage is low). Public Library of Science 2018-08-15 /pmc/articles/PMC6093690/ /pubmed/30110377 http://dx.doi.org/10.1371/journal.pone.0202420 Text en © 2018 Tchuenche et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Tchuenche, M. Gill, M. M. Bollinger, L. Mofenson, L. Phalatse, M. Nchephe, M. Mokone, M. Tukei, V. Tiam, A. Forsythe, S. Estimating the cost of diagnosing HIV at birth in Lesotho |
title | Estimating the cost of diagnosing HIV at birth in Lesotho |
title_full | Estimating the cost of diagnosing HIV at birth in Lesotho |
title_fullStr | Estimating the cost of diagnosing HIV at birth in Lesotho |
title_full_unstemmed | Estimating the cost of diagnosing HIV at birth in Lesotho |
title_short | Estimating the cost of diagnosing HIV at birth in Lesotho |
title_sort | estimating the cost of diagnosing hiv at birth in lesotho |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093690/ https://www.ncbi.nlm.nih.gov/pubmed/30110377 http://dx.doi.org/10.1371/journal.pone.0202420 |
work_keys_str_mv | AT tchuenchem estimatingthecostofdiagnosinghivatbirthinlesotho AT gillmm estimatingthecostofdiagnosinghivatbirthinlesotho AT bollingerl estimatingthecostofdiagnosinghivatbirthinlesotho AT mofensonl estimatingthecostofdiagnosinghivatbirthinlesotho AT phalatsem estimatingthecostofdiagnosinghivatbirthinlesotho AT nchephem estimatingthecostofdiagnosinghivatbirthinlesotho AT mokonem estimatingthecostofdiagnosinghivatbirthinlesotho AT tukeiv estimatingthecostofdiagnosinghivatbirthinlesotho AT tiama estimatingthecostofdiagnosinghivatbirthinlesotho AT forsythes estimatingthecostofdiagnosinghivatbirthinlesotho |